Express News | Liquidia- Intends to Defend Its Ability to Launch Yutrepia & to Defend Itself Against United's Allegations
Express News | Liquidia Corp: United Therapeutics Filed New Cross-Claims in FDA Suit Against FDA, Re-Asserting Challenge to FDA's Acceptance of Co's Yutrepia Nda
Investors Bid Liquidia (NASDAQ:LQDA) up US$119m Despite Increasing Losses YoY, Taking Three-year CAGR to 56%
Liquidia Says U.S. Court Found United Therapeutics Caused Losses of More Than $137M
With 38% Ownership in Liquidia Corporation (NASDAQ:LQDA), Institutional Investors Have a Lot Riding on the Business
Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M
Liquidia Technologies (LQDA) Soars 14.1%: Is Further Upside Left in the Stock?
Nasdaq Surges Over 200 Points; US Crude Oil Stocks Increase
Liquidia to Raise $67.5 Million From Public Offering, Private Placement of Shares
Petco, AppLovin, Dave & Buster's And Other Big Stocks Moving Higher On Wednesday
Liquidia Corporation Announces Raise of $67.5 Million From New Common Stock Financings and $32.5 Million Advance From HealthCare Royalty Under Current Financing Agreement
Express News | Liquidia Corporation Announces Raise of $67.5 Million From New Common Stock Financings and $32.5 Million Advance From Healthcare Royalty Under Current Financing Agreement
Press Release: Liquidia Corporation Announces Raise of $67.5 Million From New Common Stock Financings and $32.5 Million Advance From HealthCare Royalty Under Current Financing Agreement
Liquidia Seeks Stay on FDA Exclusivity Approval of Rival Version of Hypertension Drug
Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Liquidia to Present at Upcoming Investor Conferences
Jim Cramer Says Liquidia Corporation (LQDA) Has Been Going 'Down, Down, Down'
HC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $29 Price Target
H.C. Wainwright Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright analyst Andrew Fein maintains $Liquidia(LQDA.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 48.7% and a
Needham Reiterates Buy on Liquidia, Maintains $19 Price Target